Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Head and Neck Cancer

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 120 articles: HTML format

Single Articles

October 2025
1. YAMAMOTO E, Kumagai Y, Tachikawa T, Higashi M, et al
   Relationship Between Angiogenesis and Hypoxia-inducible Factor-1alpha and Erythropoietin in Superficial Esophageal Carcinoma.
   Anticancer Res. 2025;45:4201-4209.
   PubMed     Abstract available
   
   
   
2. HONG J, Fan R, Gao Y, Moes G, et al
   Sellar Metastatic Follicular Thyroid Carcinoma With Novel Mutations Clinically Mimicking Pituitary Macroadenoma: Intraoperative Frozen Section Diagnosis Challenges.
   Anticancer Res. 2025;45:4637-4641.
   PubMed     Abstract available
   
   
   
3. YOSHIZAWA M, Miyawaki Y, Sato H, Kawasaki T, et al
   Esophageal Lymphoepithelioma-like Carcinoma With a Remarkable Response to DCF Chemotherapy: A Case Report.
   Anticancer Res. 2025;45:4643-4652.
   PubMed     Abstract available
   
   
   
4. MAKIYAMA T, Matsumoto Y, Toyozumi T, Nakano A, et al
   Clinical Significance of Molar Count in Esophageal Squamous Cell Carcinoma: Propensity Score Matching Study.
   Anticancer Res. 2025;45:4597-4606.
   PubMed     Abstract available
   
   
   
5. HSU SW, Hsu CL, Shih HY, Chen KY, et al
   Elucidating the Genetic Contribution to Nasopharyngeal Carcinoma Risk Through Matrix Metalloproteinase-11 (MMP-11) Genotypic Analysis.
   Anticancer Res. 2025;45:4181-4192.
   PubMed     Abstract available
   
   
   September 2025
6. AMANO Y, Matsubara D, Kihara A, Yoshimoto T, et al
   The Significance of Phosphorylated Yes-associated Protein (YAP) (Ser 127) Expression in Oral Squamous Cell Carcinoma.
   Anticancer Res. 2025;45:3835-3845.
   PubMed     Abstract available
   
   
   
7. SATO F, Ono T, Hiraki A, Oka T, et al
   Prognostic Value of the C-Reactive Protein-albumin-lymphocyte Index For Patients With Recurrent omicronr Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab.
   Anticancer Res. 2025;45:3993-4004.
   PubMed     Abstract available
   
   
   
8. HIROTA J, Takeda D, Sadakane Y, Matsuzoe Y, et al
   TGF-B-induced Cancer-associated Fibroblast Activation Promotes Tumor Progression In Oral Squamous Cell Carcinoma Mouse Model.
   Anticancer Res. 2025;45:3687-3700.
   PubMed     Abstract available
   
   
   
9. SUZUKI H, Taniguchi H, Inaba Y, Tachibana H, et al
   Survival Outcome for Peptide Receptor Radionuclide Therapy in Olfactory Neuroblastoma.
   Anticancer Res. 2025;45:3877-3884.
   PubMed     Abstract available
   
   
   
10. ANZELLINI D, Loddo M, Del Bianco S
    Long-lasting Complete Remission Following Immunotherapy With Anti-PD1 Plus Anti-CTLA4 in a Polymetastatic Patient With NRAS (Q16R) Mutated Anaplastic Thyroid Carcinoma.
    Anticancer Res. 2025;45:3809-3816.
    PubMed     Abstract available
    
    
    
11. YANG TL, Chen PH, Lee HL, Jhou HJ, et al
    Tegafur-uracil as a Maintenance Therapy for Non-metastatic Nasopharyngeal Carcinoma: Insights from the Literature.
    Anticancer Res. 2025;45:3617-3628.
    PubMed     Abstract available
    
    
    August 2025
12. TERATANI Y, Sadanaga T, Wang S, Kusukawa J, et al
    Nuclear Localization of Chitinase 3-like 1 Is a Novel Biomarker for Detecting the Early Stage of Inflammation-associated Dysplasia in the Oral Cavity.
    Anticancer Res. 2025;45:3469-3478.
    PubMed     Abstract available
    
    
    
13. FUJIYOSHI K, Sugihara R, Miyamoto N, Watanabe Y, et al
    Comparison of Comprehensive Genomic Profiling Testing "Ion Torrent Genexus Sequencer" With FoundationOne.
    Anticancer Res. 2025;45:3479-3486.
    PubMed     Abstract available
    
    
    
14. TAKIMOTO R, Kamigaki T, Okada S, Ibe H, et al
    Clinical Evaluation of Immune Cell Therapy in Esophageal Cancer Resistant to Immunochemotherapy.
    Anticancer Res. 2025;45:3553-3559.
    PubMed     Abstract available
    
    
    
15. KIMURA S, Aoki M, Nishi K, Takeuchi T, et al
    CD155 Expression Predicts Poor Prognosis in OTSCC and Correlates With TIGIT Expression and Tumor Budding.
    Anticancer Res. 2025;45:3511-3522.
    PubMed     Abstract available
    
    
    
16. AOYAMA T, Maezawa Y, Hashimoto I, Kazama K, et al
    The C-reactive Protein to Albumin Ratio (CAR) Is an Independent Prognostic Factor for Recurrence in Patients With Esophageal Cancer After Esophagectomy.
    Anticancer Res. 2025;45:3365-3372.
    PubMed     Abstract available
    
    
    
17. FUJIWARA K, Mukohyama J, Kato F, Kato A, et al
    Late-onset Colonic Graft and Overlying Skin Necrosis 15 Years After Esophagectomy and Gastrectomy: A Case Report.
    Anticancer Res. 2025;45:3561-3566.
    PubMed     Abstract available
    
    
    July 2025
18. LI Y, Huang BM, Tao CC, Lan YY, et al
    Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Enhance Cisplatin-induced Apoptotic Effects via the ROS-Fas Pathway in Human NPC-TW01 Nasopharyngeal Carcinoma Cells.
    Anticancer Res. 2025;45:3117-3126.
    PubMed     Abstract available
    
    
    
19. HSU CC, Huang BM, Wu YT, Wang CC, et al
    Bis-type Triaziquone Induces Apoptotic Effects in Human OEC-M1 Oral Cancer Cells.
    Anticancer Res. 2025;45:3069-3075.
    PubMed     Abstract available
    
    
    
20. WIZIACK ZAGO PM, Hellmeister LR, Teixeira LN, DE Brito Junior RB, et al
    Cytotoxic and Metalloproteinase-inhibitory Effects of Ellagic Acid Against Oral Squamous Cell Carcinoma.
    Anticancer Res. 2025;45:2871-2880.
    PubMed     Abstract available
    
    
    
21. WON S, Hah YS, Cheon SY, Yim CD, et al
    Periostin Promotes Invasiveness and Metastasis of Oral Cancer via Epithelial-mesenchymal Transition.
    Anticancer Res. 2025;45:3099-3115.
    PubMed     Abstract available
    
    
    June 2025
22. PAPOULIAKOS S, Papanikolaou V, Chrysovergis A, Tsiambas E, et al
    C-myc Oncogene Numerical Imbalances Analysis in Laryngeal Squamous Cell Carcinoma.
    Anticancer Res. 2025;45:2377-2383.
    PubMed     Abstract available
    
    
    
23. BASKAR S, Schoeneich R, Grewal US
    In-hospital Outcomes Between Total Parenteral Nutrition and Enteral Feeding in Esophageal and Gastric Cancer: A Nationwide Analysis.
    Anticancer Res. 2025;45:2453-2457.
    PubMed     Abstract available
    
    
    
24. CHEN KY, Hsu CL, Hsu SW, Liu YF, et al
    Association of Interleukin-12A Genotypes With Nasopharyngeal Carcinoma Risk.
    Anticancer Res. 2025;45:2297-2308.
    PubMed     Abstract available
    
    
    
25. DUAH E, Poi M, Li J
    Trametinib Synergized With Abemaciclib to Inhibit Tumor Growth in Human Head and Neck Squamous Cell Carcinoma Cells.
    Anticancer Res. 2025;45:2285-2295.
    PubMed     Abstract available
    
    
    
26. KANEMITSU K, Tagayasu Y, Yamada R, Iwatsuki M, et al
    A Case of Complete Response to ICI Therapy for Unresectable Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2025;45:2689-2695.
    PubMed     Abstract available
    
    
    May 2025
27. LAI KC, Chen CW, Chang PM, Liao YC, et al
    Correlation Analysis Between IFIT2 and HLA Class II in Oral Cancer.
    Anticancer Res. 2025;45:1897-1914.
    PubMed     Abstract available
    
    
    
28. YAMAGISHI S, Kanda M, Shinozuka T, Sato Y, et al
    High Expression of OR1F1 Protein as a Potential Prognostic Biomarker for Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2025;45:1997-2009.
    PubMed     Abstract available
    
    
    
29. YAMASHITA T, Fujimasa K, Otsuka K, Saito A, et al
    Efficacy of Esophagectomy Following Neoadjuvant Chemotherapy for Esophageal Neuroendocrine Carcinoma.
    Anticancer Res. 2025;45:2051-2058.
    PubMed     Abstract available
    
    
    
30. LAI LW, Yamashita T, Otsuka K, Saito A, et al
    Rare Upper Mediastinal Oligometastasis from Early Esophagogastric Adenocarcinoma: A Case Report.
    Anticancer Res. 2025;45:2109-2114.
    PubMed     Abstract available
    
    
    
31. KITADANI J, Hayata K, Goda T, Tominaga S, et al
    The Long-term Outcomes of Borderline Resectable T3 in Locally Advanced Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Triplet Chemotherapy.
    Anticancer Res. 2025;45:2225-2235.
    PubMed     Abstract available
    
    
    April 2025
32. HAYASHI K, Ishida K, Kato M, Ohkubo S, et al
    Activation of DCTN1-RET Fusion Through Coiled-coil Domain as a Potential Target for RET Inhibitors.
    Anticancer Res. 2025;45:1407-1417.
    PubMed     Abstract available
    
    
    
33. OUCHI T, Morikawa S, Nakagawa T, Asoda S, et al
    Platelet-derived Growth Factor Receptor-alpha as a Biomarker for Tongue Spindle Cell Carcinoma.
    Anticancer Res. 2025;45:1387-1393.
    PubMed     Abstract available
    
    
    
34. HIRAKI Y, Masuda T, Motomura Y, Tobo T, et al
    Programmed Cell Death 10 (PDCD10) Is a Candidate Tumor-associated Gene in Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2025;45:1419-1433.
    PubMed     Abstract available
    
    
    March 2025
35. MA Y, Qian L, Wang D, Chen C, et al
    LncRNA XIST Promotes Proliferation, Migration and Invasion of Esophageal Squamous Cell Carcinoma Cells via Regulation of miR-186-5p/ZEB1.
    Anticancer Res. 2025;45:897-908.
    PubMed     Abstract available
    
    
    
36. IGLESIAS L, Vilchez R, Aguin S, Garcia R, et al
    Real-world Outcomes in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck With Nivolumab: Galician Study.
    Anticancer Res. 2025;45:1181-1191.
    PubMed     Abstract available
    
    
    
37. FLECKNER J, Idel C, Leichtle A, Steffen A, et al
    Elevated Plasma Interleukin-18 Levels in Head and Neck Squamous Cell Carcinoma: Correlation With IL-18 Binding Protein But Not Ferritin.
    Anticancer Res. 2025;45:943-954.
    PubMed     Abstract available
    
    
    
38. JUNG EK, Kim SA, Salam SMA, Lee KH, et al
    Role of Keratin-10 in Tumor Progression and Radioresistance of Laryngeal Cancer Cells.
    Anticancer Res. 2025;45:1035-1045.
    PubMed     Abstract available
    
    
    
39. AOKI K, Yoshitani N, Kurio N, Yoshioka N, et al
    Angiogenin-induced Osteoclastogenesis Mediates Bone Destruction in Oral Squamous Carcinoma.
    Anticancer Res. 2025;45:1025-1033.
    PubMed     Abstract available
    
    
    February 2025
40. GLITZKY S, Franzen A, Coordes A
    The Impact of Tonsillectomy on Oropharyngeal Cancer Development.
    Anticancer Res. 2025;45:709-718.
    PubMed     Abstract available
    
    
    
41. NONAKA Y, Baba T, Sugita S, Miyata K, et al
    Negative Impact of High FOXP3 Status in Lymph Nodes of Esophageal Squamous Cell Carcinoma Patients.
    Anticancer Res. 2025;45:781-787.
    PubMed     Abstract available
    
    
    January 2025
42. SUGIYAMA N, Yamada S, Nakamura Y, Morita K, et al
    Epigenetic Modification of Muscarinic Acetylcholine Receptors in Squamous Cell Carcinoma of the Head and Neck.
    Anticancer Res. 2025;45:81-95.
    PubMed     Abstract available
    
    
    
43. HIROTAKI K, Moriya S, Tomizawa K, Wakabayashi M, et al
    Prediction and Monitoring of Adaptive Radiation Therapy Timing Using Two-dimensional X-ray Image-based Water Equivalent Thickness.
    Anticancer Res. 2025;45:387-397.
    PubMed     Abstract available
    
    
    December 2024
44. BOWERS JC, Savaliya BP, Raikot SR, Ahmed SH, et al
    Survival Outcomes and Disparities in Surgery Refusal for Papillary Thyroid Cancer.
    Anticancer Res. 2024;44:5455-5461.
    PubMed     Abstract available
    
    
    
45. TORIGOE R, Oshikiri T, Goto H, Koterazawa Y, et al
    Prognostic Impact of Squamous Cell Carcinoma Antigen During Neoadjuvant Chemotherapy for Patients With Esophageal Squamous Cell Carcinoma Treated With Minimally Invasive Esophagectomy.
    Anticancer Res. 2024;44:5485-5493.
    PubMed     Abstract available
    
    
    
46. KIM D, Park YJ, Hwang YS
    Regulation of Tumor Growth and Invasion in Oral Squamous Cell Carcinoma by the Tumor Microenvironment Through the Enhancement of IGFBP-3 Expression.
    Anticancer Res. 2024;44:5337-5349.
    PubMed     Abstract available
    
    
    
47. IKAWA H, Koto M, Omatsu T, Aoki S, et al
    Prognostic Factors of Flap Complications After Carbon-ion Radiotherapy for Head and Neck Cancer With Reconstruction.
    Anticancer Res. 2024;44:5569-5576.
    PubMed     Abstract available
    
    
    
48. VASUDEVAN HN, Lazar AA, Reyes K, Rong DA, et al
    Comparison of Plasma Metagenomic Next-generation Sequencing and PCR Methods for Epstein-Barr Virus Viral Load Monitoring in Nasopharyngeal Carcinoma.
    Anticancer Res. 2024;44:5445-5453.
    PubMed     Abstract available
    
    
    November 2024
49. ESASHI R, Aoyama T, Maezawa Y, Hashimoto I, et al
    The Clinical Impact of the Systemic Immune-inflammation Index in Esophageal Cancer Patients Receiving Curative Treatment.
    Anticancer Res. 2024;44:5035-5041.
    PubMed     Abstract available
    
    
    
50. MIYASAKA Y, Kusano Y, Mizoguchi N, Takayama Y, et al
    Development of a Tumor Growth-responsive Robust Planning Method for Head and Neck Cancer in Carbon-ion Radiotherapy.
    Anticancer Res. 2024;44:5113-5122.
    PubMed     Abstract available
    
    
    October 2024
51. MIYAKE R, Takeyama H, Manome Y, Koyama M, et al
    Thyroid Cancer With Autocrine Sialyl-fibronectin Depletion Has a Poor Prognosis due to EMT Progression.
    Anticancer Res. 2024;44:4561-4568.
    PubMed     Abstract available
    
    
    
52. NA YM, Park SC, An SY, Ma HU, et al
    Analysis of Initial Outcomes of Gas-insufflation One-step Single-port Transaxillary (GOSTA) Robotic Thyroidectomy for Thyroid Cancer.
    Anticancer Res. 2024;44:4585-4592.
    PubMed     Abstract available
    
    
    
53. KUGA R, Hashimoto K, Yamamoto H, Taniguchi M, et al
    Clinicopathological Review of Head and Neck Squamous Cell Carcinomas After Neoadjuvant Chemotherapy.
    Anticancer Res. 2024;44:4593-4603.
    PubMed     Abstract available
    
    
    
54. XU L, Tian A, Fan R, Lai J, et al
    Synchronous Pancreatic Ductal Adenocarcinoma and Nasopharyngeal Carcinoma With Associated Novel Pathogenic ATM Mutation.
    Anticancer Res. 2024;44:4605-4608.
    PubMed     Abstract available
    
    
    September 2024
55. SATO M, Sato T, Hozumi C, Han Q, et al
    [(11)C]Methionine PET vs. [(18)F]Fluorodeoxyglucose PET Whole-body Imaging to Determine the Extent of Methionine-addiction Compared to Glucose-addiction of Primary and Metastatic Cancer of the Trunk in Patients.
    Anticancer Res. 2024;44:3891-3898.
    PubMed     Abstract available
    
    
    
56. HAGIWARA K, Matsuki T, Okada T, Fushimi C, et al
    Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab.
    Anticancer Res. 2024;44:4057-4072.
    PubMed     Abstract available
    
    
    
57. MATSUMURA S, Kaira K, Kuba K, Inoue H, et al
    Potential of Nutritional Markers as Predictors After Immunotherapy in Advanced Head and Neck Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:4049-4056.
    PubMed     Abstract available
    
    
    
58. HIRAKAWA H, Ikegami T, Kinjyo H, Hayashi Y, et al
    Feasibility of Near-infrared Photoimmunotherapy Combined With Immune Checkpoint Inhibitor Therapy in Unresectable Head and Neck Cancer.
    Anticancer Res. 2024;44:3907-3912.
    PubMed     Abstract available
    
    
    
59. FUJII S, Okamoto I, Okada T, Tokashiki K, et al
    Effect of Nivolumab on the Quality of Life in Recurrent/Metastatic Head and Neck Cancer.
    Anticancer Res. 2024;44:4085-4092.
    PubMed     Abstract available
    
    
    
60. CHEN CH, Chin YT, Hsu SW, Shih LC, et al
    Impact of Matrix Metalloproteinase-8 Polymorphisms on Nasopharyngeal Carcinoma Risk.
    Anticancer Res. 2024;44:3813-3820.
    PubMed     Abstract available
    
    
    
61. MATSUDA H, Iwahori K, Takeoka T, Kato R, et al
    Helicobacter pylori Infection Affects the Tumor Immune Microenvironment of Esophageal Cancer Patients.
    Anticancer Res. 2024;44:3799-3805.
    PubMed     Abstract available
    
    
    August 2024
62. HIRASAWA Y, Kubota Y, Mura E, Suzuki R, et al
    Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment.
    Anticancer Res. 2024;44:3397-3407.
    PubMed     Abstract available
    
    
    
63. RACINE F, Louandre C, Demagny J, Godin C, et al
    Transcriptional Induction of SERPINE1 and Fibrinolysis Inhibition as Predominant Effects of Glucocorticoids on the Cancer Coagulome.
    Anticancer Res. 2024;44:3269-3276.
    PubMed     Abstract available
    
    
    
64. WU J, Chun C, Lagunas AM, Crowe DL, et al
    Lysine Methyltransferase 2D Regulates Immune Response and Metastasis in Head and Neck Cancer.
    Anticancer Res. 2024;44:3231-3242.
    PubMed     Abstract available
    
    
    
65. HUBER L, Knuttel MT, Kramer B, Zaubitzer L, et al
    Influence of Tyrosine Kinase Inhibitors and Everolimus on TGFbeta1 and TGF-beta Receptor 2 in Squamous Cell Carcinoma Cells.
    Anticancer Res. 2024;44:3287-3294.
    PubMed     Abstract available
    
    
    
66. GAO A, Kim DW, Pei M, Kim KY, et al
    Implications of TP-positive CAFs in the Bone Invasion of Oral Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:3365-3374.
    PubMed     Abstract available
    
    
    July 2024
67. CHIKAMATSU K, Ida S, Masuda K, Horikawa M, et al
    Enhancement of Tumor Antigen-specific T-cell Responses by Immune Checkpoint Blockade in Human Papillomavirus-related Head and Neck Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:2921-2931.
    PubMed     Abstract available
    
    
    
68. TODA S, Saito N, Kadoya M, Okubo Y, et al
    Association of BRAF or TERT Promoter Mutations and Advanced Papillary Thyroid Carcinoma.
    Anticancer Res. 2024;44:3141-3147.
    PubMed     Abstract available
    
    
    
69. GEISTHOFF UW, Droege F, Hand C, Holtmann LC, et al
    Clinical Value of Fine Needle Aspiration Cytology and Core Needle Biopsy in Head and Neck Pathology - A Nationwide Survey in Germany.
    Anticancer Res. 2024;44:3115-3124.
    PubMed     Abstract available
    
    
    
70. SUZUKI G, Yamazaki H, Aibe N, Masui K, et al
    Optimizing Therapeutic Approaches in Superficial Esophageal Cancer: Reduced-volume Radiotherapy and Dose-dense Chemotherapy After Endoscopic Resection.
    Anticancer Res. 2024;44:3133-3139.
    PubMed     Abstract available
    
    
    June 2024
71. KRUGER K, Grust A, Muallah D, Patenge A, et al
    PIK3CA Hotspot Mutations in Saliva as a Diagnostic Marker in Oral Squamous Cell Carcinoma Patients.
    Anticancer Res. 2024;44:2369-2376.
    PubMed     Abstract available
    
    
    
72. TAI CH, Wang CC, Shih YC, Chen YJ, et al
    Functional Role of DUSP6 in the EGFR-mediated Progression of Head and Neck Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:2545-2554.
    PubMed     Abstract available
    
    
    
73. LIN CH, Chiang CC, Shih YC, Tung SL, et al
    Elucidating the Role of Let-7d-5p and OLR1 in the Progression and Prognosis of Oral Squamous Cell Carcinoma via FAK/P53 Signaling Axis.
    Anticancer Res. 2024;44:2517-2531.
    PubMed     Abstract available
    
    
    
74. HUJANEN R, Salo T, Eklund KK, Salem A, et al
    Ex Vivo Evaluation of Antiangiogenic Drugs in Oral Cancer: Potential Implications for Targeting Vasculogenic Mimicry.
    Anticancer Res. 2024;44:2377-2392.
    PubMed     Abstract available
    
    
    May 2024
75. LUKOCEVICIUTE M, Zupancic M, Kostopoulou ON, Holzhauser S, et al
    Curcumin Alone and Combined With PI3K Inhibitors Elicits Positive Effects on Oropharyngeal Cancer Cell Lines Regardless of HPV Status.
    Anticancer Res. 2024;44:1863-1876.
    PubMed     Abstract available
    
    
    
76. ICHIKAWA H, Ishikawa T, Sugai M, Muneoka Y, et al
    Prognostic Significance of NQO1 Expression in Non-neoplastic Esophageal Squamous Epithelium for Patients With Esophageal Cancer.
    Anticancer Res. 2024;44:1915-1924.
    PubMed     Abstract available
    
    
    
77. AOYAMA T, Hashimoto I, Maezawa Y, Hara K, et al
    The Prognostic Immune and Nutritional Indices Are Independent Prognostic Factors for Esophageal Cancer Patients Who Receive Curative Treatment.
    Anticancer Res. 2024;44:2185-2192.
    PubMed     Abstract available
    
    
    
78. SAMUKAWA Y, Ouchi Y, Miyashita T, Rahman A, et al
    Systemically Administered D-allose Inhibits the Tumor Energy Pathway and Exerts Synergistic Effects With Radiation.
    Anticancer Res. 2024;44:1895-1903.
    PubMed     Abstract available
    
    
    April 2024
79. KIM SI, Lee JW, Eun YG, Lee YC, et al
    Utilizing the AJCC 8(th) Staging to Discriminate Survival Outcomes in HPV-associated Oropharyngeal Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:1703-1710.
    PubMed     Abstract available
    
    
    
80. TANAKA Y, Sato Y, Horaguchi T, Fujibayashi S, et al
    Radiomics Features Using Dual-energy CT for Lymph Nodes After Preoperative Chemotherapy for Esophageal Cancer.
    Anticancer Res. 2024;44:1661-1674.
    PubMed     Abstract available
    
    
    
81. ZUPANCIC M, Nasman A, Friesland S, Dalianis T, et al
    Adenoid Cystic Carcinoma, Clinical Presentation, Current Treatment and Approaches Towards Novel Therapies.
    Anticancer Res. 2024;44:1325-1334.
    PubMed     Abstract available
    
    
    
82. NOH MH, Kim HY, Kim DH, Moon SH, et al
    Role of Peroxiredoxin 1 Induced by Epstein-Barr Virus Infection in Nasopharyngeal Carcinoma.
    Anticancer Res. 2024;44:1425-1440.
    PubMed     Abstract available
    
    
    
83. YAMAGUCHI T, Okamoto K, Saito H, Shimada M, et al
    Impact of Arteriosclerosis on Reconstruction-related Complications After Esophagectomy and Usefulness of Tailor-made Reconstruction Technique.
    Anticancer Res. 2024;44:1719-1726.
    PubMed     Abstract available
    
    
    March 2024
84. KODAMA H, Kadowaki S, Nakazawa T, Matsubara Y, et al
    Safety and Efficacy of Gemcitabine Plus Cisplatin Against Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective Study.
    Anticancer Res. 2024;44:1227-1232.
    PubMed     Abstract available
    
    
    
85. EDEN D, Ghose A, Moschetta M, Perez-Fidalgo JA, et al
    Immunotherapy Combined With Standard Therapies in Head and Neck Squamous Cell Carcinoma - A Meta-analysis.
    Anticancer Res. 2024;44:861-878.
    PubMed     Abstract available
    
    
    
86. SOHDA M, Hara K, Kuriyama K, Tateno K, et al
    Effectiveness of Combination Chemotherapy With Docetaxel, Nedaplatin, and 5-Fluorouracil for Advanced and Recurrent Esophageal Cancer.
    Anticancer Res. 2024;44:1309-1315.
    PubMed     Abstract available
    
    
    
87. BAUDREXL J, Sakkas A, Pietzka S, Derka S, et al
    Evaluation of Five-year Overall Survival Rates Among 18,331 Head and Neck Cancer Patients Exposed to Different Targeted Therapies Through Real-world Data in a Case-controlled Study.
    Anticancer Res. 2024;44:1247-1270.
    PubMed     Abstract available
    
    
    
88. CHEN PH, Lu HK, Renn TY, Chang TM, et al
    Plumbagin Induces Reactive Oxygen Species and Endoplasmic Reticulum Stress-related Cell Apoptosis in Human Oral Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:1173-1182.
    PubMed     Abstract available
    
    
    
89. MACHIDA T, Sakuma K, Fuwa N, Tanaka A, et al
    Local Low-dose Anti-PD-L1 Antibodies Improve Antitumor Effects in Oral Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:993-1002.
    PubMed     Abstract available
    
    
    February 2024
90. AOYAMA T, Hashimoto I, Maezawa Y, Hara K, et al
    CRP-albumin-lymphocyte (CALLY) Index Is an Independent Prognostic Factor for the Esophageal Cancer Patients Who Received Curative Treatment.
    Anticancer Res. 2024;44:815-822.
    PubMed     Abstract available
    
    
    
91. ZOU X, Lin Y, Ren H, Meng Y, et al
    PRMT5-PAK1 Signaling Participates in Metastasis and Is Associated With Poor Prognosis in Human Esophageal Carcinoma.
    Anticancer Res. 2024;44:593-604.
    PubMed     Abstract available
    
    
    
92. HERAMB-AAMOT J, Mala T, Fauske L
    Everyday Life Six to Eight Months After Esophagectomy for Cancer: A Qualitative Study.
    Anticancer Res. 2024;44:743-750.
    PubMed     Abstract available
    
    
    January 2024
93. AOYAMA T, Kato A, Maezawa Y, Hashimoto I, et al
    Lymphocyte to Monocyte Ratio Is an Independent Prognostic Factor in Patients With Esophageal Cancer Who Receive Curative Treatment.
    Anticancer Res. 2024;44:339-346.
    PubMed     Abstract available
    
    
    
94. BAUDREXL J, Pietzka S, Scheurer M, Schramm A, et al
    Sex-specific Real-World 5-year Overall Survival Rates for (Radio)chemotherapy, Targeted Therapy, and Combinations in Patients With Head and Neck Cancer.
    Anticancer Res. 2024;44:267-286.
    PubMed     Abstract available
    
    
    
95. LEE S, Fujiwara Y, Gyobu K, Tamura T, et al
    Evaluation of Intraoperative Neural Monitoring During Thoracoscopic Surgery for Esophageal Cancer.
    Anticancer Res. 2024;44:157-166.
    PubMed     Abstract available
    
    
    
96. AOYAMA T, Kato A, Hashimoto I, Maezawa Y, et al
    Pretreatment Fibrinogen Level Is a Prognostic Factor for Esophageal Cancer Patients Who Receive Curative Treatment.
    Anticancer Res. 2024;44:249-255.
    PubMed     Abstract available
    
    
    
97. KATO A, Aoyama T, Maezawa Y, Hashimoto I, et al
    Geriatric Nutritional Risk Index Is an Independent Prognostic Factor for Patients With Esophageal Cancer Who Receive Curative Treatment.
    Anticancer Res. 2024;44:331-337.
    PubMed     Abstract available
    
    
    
98. TSUCHIDA K, Shiga K, Katagiri K, Saito D, et al
    Increasing Patients With HPV-positive Oropharyngeal Squamous Cell Carcinoma and its Oncologic Outcomes in the Rural Region in Northern Japan.
    Anticancer Res. 2024;44:403-407.
    PubMed     Abstract available
    
    
    
99. YOSHIMURA N, Fujiwara M, Igeta M, Suzuki H, et al
    Risk Factors Causing Hypothyroidism in Patients With Head and Neck Cancer After Radiotherapy Using SIB-VMAT.
    Anticancer Res. 2024;44:323-329.
    PubMed     Abstract available
    
    
    
100. SUGASE T, Kanemura T, Takeoka T, Matsuura N, et al
     Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma.
     Anticancer Res. 2024;44:185-193.
     PubMed     Abstract available
     
     
     
101. EBELING M, Derka S, Baudrexl J, Sakkas A, et al
     Ibuprofen Reduces 5-Year Overall Survival of Head and Neck Cancer Patients With Immunotherapy - A Retrospective Case-controlled Real-World Data Analysis of 10,000 Patients.
     Anticancer Res. 2024;44:313-322.
     PubMed     Abstract available
     
     
     December 2023
102. ASANUMA K, Ishihara M, Nakamura T, Uchida K, et al
     Histological Assessment of Synovial Sarcoma Before and After TCR-T Cell Therapy and Cryoablation: A Case Report.
     Anticancer Res. 2023;43:5737-5748.
     PubMed     Abstract available
     
     
     
103. SUZUKI H, Haimoto S, Inaba Y, Tachibana H, et al
     Peptide Receptor Radionuclide Therapy for Recurrent Olfactory Neuroblastoma After Cranioplasty for Surgical Infection: A Case Report.
     Anticancer Res. 2023;43:5723-5728.
     PubMed     Abstract available
     
     
     
104. SAMARA W, Moztarzadeh O, Pernicky J, Baghalipour N, et al
     Carotid Artery Stenosis on Panoramic Radiographs and CT Scans in Patients With Malignancies After Radiotherapy.
     Anticancer Res. 2023;43:5657-5662.
     PubMed     Abstract available
     
     
     
105. IDEL C, Ribbat-Idel J, VON Bernuth A, Fleckner J, et al
     Correlation of Intra-tumoral and Peripheral PD-1/PD-L1 Immunity in Head and Neck Cancer.
     Anticancer Res. 2023;43:5349-5358.
     PubMed     Abstract available
     
     
     
106. BURYSKA S, Patel K, Wuertz B, Gaffney PM, et al
     Potential Roles of Activin in Head and Neck Squamous Cell Carcinoma Progression and Mortality.
     Anticancer Res. 2023;43:5299-5310.
     PubMed     Abstract available
     
     
     November 2023
107. HSU CC, Wu YT, Yu SJ, Chen PJ, et al
     NAD(P)H:quinone Oxidoreductase 1 Is Involved in AZ-1-induced Apoptotic Effects in Nasopharyngeal Carcinoma TW01 Cells.
     Anticancer Res. 2023;43:4879-4885.
     PubMed     Abstract available
     
     
     
108. WATANABE H, Kano K, Hashimoto I, Tanabe M, et al
     Intraoperative Blood Loss Impacts Recurrence and Survival in Patients With Locally Advanced Esophageal Cancer.
     Anticancer Res. 2023;43:5173-5179.
     PubMed     Abstract available
     
     
     
109. NATSUKI S, Miki Y, Tanaka H, Nishiyama M, et al
     Usefulness of Biopsy Specimens for Evaluating CD103(+) Tumor-resident Memory T Cells in Esophageal Cancer.
     Anticancer Res. 2023;43:4823-4832.
     PubMed     Abstract available
     
     
     
110. FUKUSHIMA H, Naruse T, Furukawa K, Omori K, et al
     Extranodal Extension and Epithelial Cell Adhesion Molecule Over-expression in Oral Squamous Cell Carcinoma.
     Anticancer Res. 2023;43:5155-5166.
     PubMed     Abstract available
     
     
     
111. CHEN H, Pei M, Shin SW, Moon S, et al
     Implication of TIPE2 Expression on the Malignant Transformation of Oral Leukoplakia.
     Anticancer Res. 2023;43:4937-4946.
     PubMed     Abstract available
     
     
     
112. ISHIDA Y, Shintani T, Nobumoto T, Sakurai S, et al
     Interaction of Integrin alphavbeta8 With Type I Collagen Promotes Squamous Cell Carcinoma Cell Motility via RAC1 Activation.
     Anticancer Res. 2023;43:4833-4841.
     PubMed     Abstract available
     
     
     
113. KOWKABANY G, Jimenez PB, Sharan S, Bansal S, et al
     Inequities in Time to Treat Thyroid Cancer.
     Anticancer Res. 2023;43:5025-5030.
     PubMed     Abstract available
     
     
     
114. KANEMOTO H, Obata K, Umemori K, Hasegawa K, et al
     Multimodal Prediction of Cervical Lymph Node Metastasis and Recurrence in Oral Squamous Cell Carcinoma.
     Anticancer Res. 2023;43:4993-5001.
     PubMed     Abstract available
     
     
     
115. ASAKA S, Shimakawa T, Nishiguchi R, Yamaguchi K, et al
     Preoperative and Postoperative C-Reactive Protein to Albumin Ratio (CAR) as a Prognostic Marker for Survival of Esophageal Squamous Cell Carcinoma Patients After Surgery.
     Anticancer Res. 2023;43:5139-5147.
     PubMed     Abstract available
     
     
     October 2023
116. ZHOU J, Liu J, Zhang KE, Lv J, et al
     High-throughput Sequencing Analysis of Differentially Expressed microRNAs Associated With SREBP1 in Differentiated Thyroid Carcinoma.
     Anticancer Res. 2023;43:4435-4446.
     PubMed     Abstract available
     
     
     
117. DURZYNSKA M, Dos Santos FLC, Michalek IM
     Clinicopathological Characteristics, Survival Outcomes, and Prognostic Factors in Adult Patients With Sinonasal Rhabdomyosarcoma: Insights from a Retrospective Cohort Study.
     Anticancer Res. 2023;43:4517-4524.
     PubMed     Abstract available
     
     
     
118. DURZYNSKA M, Dos Santos FLC, Matuszczyk A, Derezinska-Wolek E, et al
     Prognostic Implications of PRAME Expression and Clinicopathological Factors in Sinonasal Mucosal Melanoma: A Single-center Cohort Study of 30 Cases.
     Anticancer Res. 2023;43:4551-4557.
     PubMed     Abstract available
     
     
     
119. TAKEHARA Y, Tamaki T, Mimura K, Saito K, et al
     Immunological Responses Associated With Neoadjuvant Therapy in the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma.
     Anticancer Res. 2023;43:4691-4700.
     PubMed     Abstract available
     
     
     
120. DUMITRU CS, Raica M
     Vascular Endothelial Growth Factor Family and Head and Neck Squamous Cell Carcinoma.
     Anticancer Res. 2023;43:4315-4326.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.